|
Back to Home » January 2020 News » Expert Evaluation Clarifies Phase 3 Results and Provides Strong Support for MOB-015 |
Expert Evaluation Clarifies Phase 3 Results and Provides Strong Support for MOB-015 |
January 22, 2020
STOCKHOLM, Jan. 22, 2020 /PRNewswire/ -- Moberg Pharma AB (OMX: MOB) has now completed the expert evaluation of the results from the North American Phase 3-study. The analysis conducted with key opinion leaders (KOLs) has confirmed the validity of the data presented in December 2019 and...
Source URL: https://www.prnewswire.com:443/news-releases/expert-evaluation-clarifies-phase-3-results-and-provides-strong-support-for-mob-015-300990988.html
|
|
|
|
